4-(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)naphthalene-1-carbonitrile

AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator. Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the anabolic action of testosterone, but only around 27% of its potency as an androgen.